TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02635217

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation
Description: using an automated carbon dioxide insufflator the gas will be infused on demand during the endoscopies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation
Description: using an automated carbon dioxide insufflator the gas will be infused on demand during the endoscopies

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: room air insufflation
Description: using standard care room air will be infused on demand

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: room air insufflation
Description: using standard care room air will be infused on demand

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EGD (Esophagogastroduodenoscopy) before Colonoscopy
Description: the order of endoscopies will be randomized as well

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EGD (Esophagogastroduodenoscopy) before Colonoscopy
Description: the order of endoscopies will be randomized as well

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy before EGD (Esophagogastroduodenoscopy)

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy before EGD (Esophagogastroduodenoscopy)
Study: NCT03997214

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory muscle strength training
Description: The experimental group received the intervention of inspiratory muscles training 5times/week for 6 weeks, 5days/ per cycle; the patients stayed in the semi-recumbent position, recorded the initial/first measurement of MIP. The trigger sensitivity was adjusted to 10% of the first recorded MIP at the start of training, then reducing the ventilator trigger sensitivity and training duration weekly.
Study: NCT00289874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo. Up to 3 weeks of treatment
Study: NCT00775268

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomography
Description: Imaging

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomography
Description: Imaging

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [3'-deoxy-3'-[F-18] fluorothymidine
Description: Undergo scans

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [3'-deoxy-3'-[F-18] fluorothymidine
Description: Undergo scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo scans

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fine-needle aspiration
Description: sample collected
Study: NCT04051528

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guiding training
Description: At the first time in guiding training will focus on introducing the Goal-Plan-Do-Check strategy and identifying initial three goals by the Canadian Occupational Performance Measure. At the second time in guiding training will begin with a review of the Goal-Plan-Do-Check and will apply the Goal-Plan-Do-Check to the first initial goal. Participants will review this goal and plan, describe the execution of the plan (do), and evaluate the execution of the plan (check). After each execution of the plan, the participant will rate his performance using the COPM Performance Scale, producing iterative scores for each activity. The remaining session of guiding sessions will repeat this process, review performance of identified activities, and applying the Goal-Plan-Do-Check strategy to improve performance.
Study: NCT00365508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine lozenge
Description: nicotine lozenge
Study: NCT03109405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation-assisted venous access
Description: Stimulation-assisted venous access

Intervention type: OTHER
Group type: OTHER
Intervention: 20 guage cannula for IV, tourniquet optional
Description: Standard IV cannulation using 20 ga needle, and use of tourniquet at discretion of nurse performing IV cannulation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20 guage cannula for IV, tourniquet optional
Description: Standard IV cannulation using 20 ga needle, and use of tourniquet at discretion of nurse performing IV cannulation
Study: NCT00365508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: transdermal nicotine patch
Study: NCT02267083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GPX-150 for Injection
Description: GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
Study: NCT03192098

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Savary bougie dilation
Description: Patients will be dilated with the use of the Savary bougienage device

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Savary bougie dilation
Description: Patients will be dilated with the use of the Savary bougienage device
Study: NCT03147183

Intervention type: DRUG
Intervention: Thymoglobulin
Description: This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
Study: NCT03413904

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transanal TME
Description: transanal approach to TME in rectal cancer

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic TME
Description: laparoscopic approach to TME in rectal cancer
Study: NCT00838708

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRD174 Cream
Description: topical SRD174 Cream

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vehicle cream
Description: topical vehicle cream
Study: NCT04691050

Intervention type: PROCEDURE
Group type: OTHER
Intervention: OrthoMTA (BioMTA)
Description: Primary second molars without successors in which traditional root canal treatment with gutta-percha could not be performed was treated with OrthoMTA
Study: NCT03660358

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinesiotape application
Description: kinesiotape application to diaphragm, chest wall and abdomen in preterm infants.
Study: NCT04009538

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: exercise program twice a week
Study: NCT00472836

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Administration of CP-945,598 in subjects with normal renal function.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Administration of CP-945,598 in subjects with severe renal impairment.
Study: NCT01678053

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole (proton pump inhibitor)
Description: Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.

Intervention type: DRUG
Group type: OTHER
Intervention: omeprazole (proton pump inhibitor)
Description: Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
Study: NCT01679587

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: 20 mg molidustat as a single tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: 20 mg molidustat as a single tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: 20 mg molidustat as a single tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molidustat (BAY85-3934)
Description: 20 mg molidustat as a single tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of matching placebo will be given in each treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of matching placebo will be given in each treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of matching placebo will be given in each treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single oral dose of matching placebo will be given in each treatment arm
Study: NCT02494102

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modafinil
Description: Atypical Psychomotor stimulant

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00474851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone acetate + estrogens
Description: Norethindrone acetate 5 mg by mouth daily + Conjugated equine estrogens 0.625 mg by mouth daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: norethindrone acetate + placebo
Description: norethindrone acetate 5 mg by mouth daily + Placebo capsule 1 pill by mouth daily
Study: NCT02963870

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Security Plan
Description: This study compared two groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with the Security Plan plus the usual treatment and a group receiving standard treatment only.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Security Plan
Description: This study compared two groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with the Security Plan plus the usual treatment and a group receiving standard treatment only.
Study: NCT03483168

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Culturally sensitive pain education
Description: The content of the PNE program include the characteristics of acute and chronic pain, purpose of acute pain, formation process of acute pain from the nervous system, the formation process of chronic pain, and potential sustaining factors for central sensitization.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard pain education program
Description: For the standard translated PNE, The English translation of Pain Neuroscience Education: slides for supporting and illustrating your explanation at the Pain in Motion Group web page (http://www.paininmotion.be/education/tools-for-clinical-practice) and English translation of the Patient Information Leaflet will be used. The education materials will be translated using the forward/backward translation process. The English version of PNE presentation and information leaflet will be translated to Turkish by two independent translators.
Study: NCT04205396

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Written emotional disclosure
Description: Participants will write five stories (days 8, 11, 14, 17 and 20) about an assigned topic relating to their experiences as a caregiver of someone with advanced liver disease. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience training
Description: Participants will write three things that went well at the end of their day (before going to sleep), and what was their role in bringing them. These will be done about every three days (days 8, 11, 14, 17 and 20) for 2 weeks at home. Rules for the exercise will be provided in an instructions page. Additionally, baseline and outcome measures will be completed.

Intervention type: OTHER
Group type: OTHER
Intervention: No treatment
Description: Participants will complete baseline and outcome assessments and no intervention will be conducted.
Study: NCT01378455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: interactive computerized handwriting training program
Description: In ICHTP group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software. The training program costs 45 min/once, three times/one week, and sustains four weeks.In traditional group, they received the training of paper-pencil activities with visual-perception and visual-motor integration skills. The training duration is as long as ICHTP group.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional handwriting training program
Description: The THTP group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
Study: NCT00712985

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zometa
Description: Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose
Study: NCT01553279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V419
Description: Diphtheria and Tetanus toxoids and acellular Pertussis adsorbed, inactivated Poliovirus, Haemophilus b conjugate \[meningococcal outer membrane protein complex\], and Hepatitis B \[recombinant\] vaccine administered via 0.5 mL intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: V419
Description: Diphtheria and Tetanus toxoids and acellular Pertussis adsorbed, inactivated Poliovirus, Haemophilus b conjugate \[meningococcal outer membrane protein complex\], and Hepatitis B \[recombinant\] vaccine administered via 0.5 mL intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PREVNAR 13®
Description: Pneumococcal conjugate vaccine (13-valent, adsorbed) administered via 0.5 mL intramuscular injection (routine vaccination).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PREVNAR 13®
Description: Pneumococcal conjugate vaccine (13-valent, adsorbed) administered via 0.5 mL intramuscular injection (routine vaccination).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCC-TT
Description: Meningococcal Group C polysaccharide conjugate vaccine to tetanus toxoid adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MCC-CRM
Description: Meningococcal Group C conjugate vaccine to CRM-197 adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib-MCC
Description: Haemophilus type b and meningococcal Group C conjugate vaccine administered via 0.5 mL intramuscular injection.
Study: NCT04000919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: L-DOPA
Description: L-DOPA/carbidopa (50-200 mg L-DOPA/50 mg carbidopa)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Carbidopa
Description: Carbidopa (50mg)
Study: NCT02099396

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel+lobaplatin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine+lobaplatin
Study: NCT04846166

Intervention type: DIAGNOSTIC_TEST
Intervention: Periodontally healthy group
Description: probing pocket depth (PPD)≤ 3 mm (presence of normal gingival sulcus), bleeding on probing (BOP) \< 10%, clinical absence of periodontal inflammation, radiological bone loss, and any prior periodontal disease, additionally presence of anatomically intact periodontium

Intervention type: DIAGNOSTIC_TEST
Intervention: Periodontitis
Description: : interdental clinical attachment level (CAL) ≥ 5 mm and PPD ≥ 6 mm on at least two non-adjacent teeth, bone loss involving the middle or apical third of the root radiographically, moderate ridge defect and ≥30% of teeth
Study: NCT01553279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hib-MCC
Description: Haemophilus type b and meningococcal Group C conjugate vaccine administered via 0.5 mL intramuscular injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR Vaccine
Description: Measles, mumps, and rubella vaccine (live) given via 0.5 mL intramuscular injection (routine vaccination).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MMR Vaccine
Description: Measles, mumps, and rubella vaccine (live) given via 0.5 mL intramuscular injection (routine vaccination).
Study: NCT00633516

Intervention type: DEVICE
Intervention: Optical Spectroscopy
Description: Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
Study: NCT02341950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCI Hard
Description: The game SCI Hard is designed to enhance self-management skills in individuals with spinal cord injury
Study: NCT00577902

Intervention type: OTHER
Intervention: Observation
Description: Head and neck cancer patients receiving chemoradiation
Study: NCT03026855

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous PRP Gel and PRP Injection
Description: Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer.~Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound.~Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment.
Study: NCT03596931

Intervention type: DRUG
Intervention: Statins (Cardiovascular Agents)
Description: Prescribed with statins
Study: NCT01622374

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Ten minutes of music or silence were applied prior to dental procedures

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Ten minutes of music or silence were applied prior to dental procedures

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music
Description: Ten minutes of music or silence were applied prior to dental procedures

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Music
Description: Ten minutes of music or silence were applied prior to dental procedures
Study: NCT01587586

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: PEGASYS 180 µg Q1W
Description: 48 doses, solution, 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P1101 180 µg Q1W, 48 doses
Description: 48 doses, solution, 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P1101 270µg Q1W, 48 doses
Description: 48 doses, solution, 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P1101 450µg Q2W, 24 doses
Description: 24 doses, solution, 48 weeks
Study: NCT01383798

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 100 mg lactose per day for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: 100 mg per day of ferrous sulfate for 6 weeks
Study: NCT05820867

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single-Session Bilateral Mandibular Third Molar Extraction
Description: Participants in this group chose to have both of their lower mandibular third molars extracted during a single appointment. This group will be used to compare the impact of single-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Two-Session Bilateral Mandibular Third Molar Extraction
Description: Participants in this group chose to have their lower mandibular third molars extracted during two separate appointments. This group will be used to compare the impact of two-session extraction on patients' oral health-related quality of life, postoperative pain, and maximum interincisal opening.
Study: NCT01303705

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-OX40
Description: Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8 of the study. The total anti-OX40 dose will be reconstituted in 100 ml 0.9% saline and infused over no more than 60 minutes intravenously. A single-use non-pyrogenic durapore membrane low protein binding filter (e.g.: Braun 1.2 micron air eliminating filter or equivalent) shall be used to filter the study product in the line between infusion bag and patient.
Study: NCT00823940

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1362885
Description: 5 - 100mg of GSK1362885 or placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1362885
Description: 100 - 600mg or placebo
Study: NCT04375527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Binimetinib
Description: Given PO

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02047448

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pharmacist Counseling
Description: The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.